PIQUR Therapeutics is a Swiss pharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapies using proprietary drug design methodologies. The company addresses the need for more effective cancer treatments by focusing on precision medicine to improve patient outcomes and reduce side effects.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack the precision needed to target cancer cells effectively, leading to significant side effects and suboptimal patient outcomes. There is a need for therapies that can selectively target cancer cells while sparing healthy tissue.
Solution
PIQUR Therapeutics is a pharmaceutical company focused on developing targeted anti-cancer therapies through proprietary drug design methodologies. By focusing on precision medicine, PIQUR aims to create more effective cancer treatments that improve patient outcomes and reduce adverse effects. Their approach involves designing drugs that selectively target specific molecular pathways or biomarkers present in cancer cells, minimizing harm to healthy cells.
Target Audience
PIQUR's primary target audience includes oncology researchers, medical professionals specializing in cancer treatment, and pharmaceutical companies seeking innovative cancer therapies.
Features
- Proprietary drug design methodologies for creating targeted therapies
- Focus on precision medicine to improve treatment efficacy
- Development of therapies that selectively target cancer cells
- Aim to reduce side effects associated with traditional cancer treatments